Filing Flows › Ultragenyx Pharmaceutical (RARE) › R&D spending
Ultragenyx Pharmaceutical (RARE) R&D spending by quarter
Ultragenyx Pharmaceutical's R&D spending was $154M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 7 quarters it ranged from $154M (Q3 2026) to $216M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $154M | -8% | -29% |
| Q2 2026 | $167M | -11% | +1% |
| Q1 2026 | $187M | -8% | +13% |
| Q4 2025 | $203M | -6% | — |
| Q3 2025 | $216M | +31% | — |
| Q2 2025 | $165M | -0.6% | — |
| Q1 2025 | $166M | — | — |
Q3 2026 at a glance
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ultragenyx Pharmaceutical's R&D spending?
Ultragenyx Pharmaceutical's R&D spending was $154M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Ultragenyx Pharmaceutical's R&D spending changed?
Over the last 7 quarters it ranged from $154M (Q3 2026) to $216M (Q3 2025).
Q3 2026 results → · How Ultragenyx Pharmaceutical makes money →